CHMP positive for Attrogy ( diflunisal) to treat hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.- Purpose Pharma
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Attrogy , intended for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
The benefits of Attrogy are its ability to delay disease progression, measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7), at 2 years of treatment versus placebo, as shown in a randomised, double-blind, placebo-controlled clinical trial. The most common side effects are gastro-intestinal.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.